{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:40:20Z","timestamp":1790214020542,"version":"4.1.0"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ibroneuroscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.neuroscience.2025.12.053","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T23:19:23Z","timestamp":1766272763000},"page":"45-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Antibody drug conjugates in Alzheimer\u2019s disease: emerging strategies and future directions"],"prefix":"10.1016","volume":"596","author":[{"given":"Mandana","family":"AmeliMojarad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melika","family":"AmeliMojarad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2025.12.053_b0005","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s11033-018-4427-x","article-title":"Monoclonal antibodies in cancer immunotherapy","volume":"45","author":"Kimiz-Gebologlu","year":"2018","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0010","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0015","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.535","article-title":"The pharmacology and therapeutic applications of monoclonal antibodies","volume":"7","author":"Castelli","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-025-00465-w","article-title":"Second-generation anti-amyloid monoclonal antibodies for Alzheimer\u2019s disease: current landscape and future perspectives","volume":"14","author":"Kim","year":"2025","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0025","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0030","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrd3505","article-title":"The amyloid cascade hypothesis for Alzheimer\u2019s disease: an appraisal for the development of therapeutics","volume":"10","author":"Karran","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0035","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14856","article-title":"The neuroinflammatory role of microglia in Alzheimer\u2019s disease and their associated therapeutic targets","volume":"30","author":"AmeliMojarad","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0040","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: successes, limitations and hopes for the future","volume":"157","author":"Chames","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0045","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2217\/imt-2018-0081","article-title":"Pros and cons of the immunogenicity of monoclonal antibodies in cancer treatment: a lesson from autoimmune diseases","volume":"11","author":"Talotta","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2024.148607","article-title":"Emerging trends and therapeutic applications of monoclonal antibodies","volume":"925","author":"Mekala","year":"2024","journal-title":"Gene"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0055","doi-asserted-by":"crossref","DOI":"10.1186\/s43556-024-00210-1","article-title":"Monoclonal antibodies: from magic bullet to precision weapon","volume":"5","author":"Aboul-Ella","year":"2024","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-drug conjugates: a comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1274088","article-title":"A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy","volume":"14","author":"Riccardi","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0070","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0075","first-page":"3055","article-title":"Value of HAMA-derermination in clinical practice-an overview","volume":"17","author":"Hasholzner","year":"1997","journal-title":"Anticancer Res"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0080","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40262-025-01508-1","article-title":"Population pharmacokinetics for belantamab mafodotin monotherapy and combination therapies in patients with relapsed\/refractory multiple myeloma","volume":"64","author":"Papathanasiou","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-023-00976-6","article-title":"Clinical trials of new drugs for Alzheimer disease: a 2020\u20132023 update","volume":"30","author":"Huang","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0090","doi-asserted-by":"crossref","first-page":"14794","DOI":"10.3390\/ijms241914794","article-title":"Amyloid precursor protein and Alzheimer\u2019s disease","volume":"24","author":"Orobets","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0095","doi-asserted-by":"crossref","DOI":"10.1002\/alz.047259","article-title":"Emerge and Engage topline results: phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"16","author":"Haeberlein","year":"2020","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0100","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jconrel.2024.01.047","article-title":"Alzheimer\u2019s disease current therapies, novel drug delivery systems and future directions for better disease management","volume":"367","author":"Singh","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0105","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009835","article-title":"Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates","volume":"6","author":"Yu","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0110","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1039\/D2CS00141A","article-title":"Degrader-antibody conjugates","volume":"51","author":"Dragovich","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0115","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-1-60761-895-9_14","article-title":"Enzyme-nanoparticle conjugates for biomedical applications","volume":"679","author":"Vertegel","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0120","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3390\/cancers17091591","article-title":"Exploring the role of ADCs in brain metastases and primary brain tumors: insight and future directions","volume":"17","author":"Bruzzone","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0125","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0130","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0135","article-title":"Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: challenges, successes and future","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0140","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.862369","article-title":"Amyloid-related imaging abnormalities with anti-amyloid antibodies for the treatment of dementia due to Alzheimer\u2019s disease","volume":"13","author":"Withington","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0145","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/13872877251361049","article-title":"The structural foundations of anti-amyloid-\u03b2 immunotherapies: unravelling antibody-antigen interactions in Alzheimer\u2019s disease treatment","volume":"107","author":"Miles","year":"2025","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-025-03546-9","article-title":"Microglial glycolytic reprogramming in alzheimer\u2019s disease: association with impaired phagocytic function and altered vascular proximity","volume":"22","author":"Lu","year":"2025","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0155","first-page":"1","article-title":"Glymphatic system clearance and Alzheimer\u2019s disease risk: a CSF proteome-wide study","volume":"17","author":"Cullell","year":"2025","journal-title":"Alzheimer\u2019s Research and Therapy"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0160","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/978-3-031-31570-1_16","article-title":"Beyond APP, PSEN1, PSEN2, and APOE: what else does the genome tell us?","author":"Behl","year":"2023","journal-title":"Alzheimer\u2019s Disease Res."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2024.105761","article-title":"Advances in Alzheimer\u2019s disease: a multifaceted review of potential therapies and diagnostic techniques for early detection","volume":"177","author":"Sharma","year":"2024","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0170","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-drug conjugate-based therapeutics: state of the science","volume":"111","author":"Birrer","year":"2019","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0175","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202500305","article-title":"Advanced antibody\u2013drug conjugates design: innovation in linker chemistry and site-specific conjugation technologies","volume":"26","author":"Matsuda","year":"2025","journal-title":"Chembiochem"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110539","article-title":"Postulating the possible cellular signalling mechanisms of antibody drug conjugates in Alzheimer\u2019s disease","volume":"102","author":"Punyakoti","year":"2023","journal-title":"Cell. Signal."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0185","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/14712598.2024.2416947","article-title":"A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer\u2019s disease","volume":"24","author":"Chhabra","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0190","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.eng.2020.06.030","article-title":"Modified therapeutic antibodies: improving efficacy","volume":"7","author":"Dai","year":"2021","journal-title":"Engineering"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0195","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.3390\/cancers12103041","article-title":"Fc-engineered antibodies with enhanced Fc-Effector function for the treatment of B-cell malignancies","volume":"12","author":"van der Horst","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0200","doi-asserted-by":"crossref","unstructured":"Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D.M., Chen, L., 2007. Immunostimulatory monoclonal antibodies for cancer therapy, Nature Reviews Cancer, 7(2),95\u2013106. 10.1038\/nrc2051.","DOI":"10.1038\/nrc2051"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0205","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody\u2013drug conjugates: recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0210","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.118010","article-title":"The journey of antibody-drug conjugates for revolutionizing cancer therapy: a review","volume":"117","author":"Akram","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0220","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0225","doi-asserted-by":"crossref","DOI":"10.1186\/s12987-020-00230-3","article-title":"A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity","volume":"17","author":"Kadry","year":"2020","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0230","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.2174\/1381612822666160720163656","article-title":"Strategies that target tight junctions for enhanced drug delivery","volume":"22","author":"Gonz\u00e1lez-Mariscal","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0235","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1021\/acsmedchemlett.1c00225","article-title":"Conjugation of a blood brain barrier peptide shuttle to an Fc domain for brain delivery of therapeutic biomolecules","volume":"12","author":"Cavaco","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113595","article-title":"Mechanisms of receptor-mediated transcytosis at the blood-brain barrier","volume":"381","author":"Baghirov","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0245","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1039\/D2SC05678J","article-title":"Compact hydrophilic electrophiles enable highly efficacious high DAR ADCs with excellent in vivo PK profile","volume":"14","author":"Ochtrop","year":"2023","journal-title":"Chem. Sci."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0250","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1080\/17425247.2023.2255138","article-title":"Receptor-mediated transcytosis of macromolecules across the blood-brain barrier","volume":"20","author":"Baghirov","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0255","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16152681","article-title":"Single-domain antibodies as antibody-drug conjugates: from promise to practice-a systematic review","volume":"16","author":"Medina P\u00e9rez","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114165","article-title":"Albubody: an engineered scFv variant platform for site-specific drug conjugation and enhanced tumor efficacy","volume":"386","author":"Kwon","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0265","doi-asserted-by":"crossref","unstructured":"Yang, H.M., 2025. Recent advances in antibody therapy for alzheimer\u2019s disease: focus on bispecific antibodies, Int. J. Mol. Sci., 26, 6271. 10.3390\/IJMS26136271.","DOI":"10.3390\/ijms26136271"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100214","article-title":"Bispecific brain-penetrant antibodies for treatment of Alzheimer\u2019s disease","volume":"12","author":"Sehlin","year":"2025","journal-title":"J. Prev Alzheimers Dis."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0275","article-title":"Recent advances in antibody therapy for Alzheimer\u2019s disease: focus on bispecific antibodies","volume":"26","author":"Yang","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107386","article-title":"Research progress of PROTACs for neurodegenerative diseases therapy","volume":"147","author":"Cai","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0285","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.7150\/thno.55680","article-title":"A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0290","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/2472555220965528","article-title":"E3 ligase ligands for PROTACs: how they were found and how to discover new ones","volume":"26","author":"Ishida","year":"2021","journal-title":"SLAS Discovery"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0295","doi-asserted-by":"crossref","unstructured":"Wang, H., Zhou, R., Xu, F., Yang, K., Zheng, L., Zhao, P., Shi, G., Dai, L., Xu, C., Yu, L., Li, Z., Wang, J., Wang, J., 2023. Beyond canonical PROTAC: biological targeted protein degradation (bioTPD), Biomater. Res., 1(27), 72, 10.1186\/S40824-023-00385-8.","DOI":"10.1186\/s40824-023-00385-8"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0300","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202500262","article-title":"Linker design for the antibody drug conjugates: a comprehensive review","volume":"20","author":"Lei","year":"2025","journal-title":"ChemMedChem"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0305","doi-asserted-by":"crossref","unstructured":"De Strooper, B., 2010. Proteases and proteolysis in alzheimer disease: a multifactorial view on the disease process, 465\u2013494. 10.1152\/PHYSREV.00023.2009.","DOI":"10.1152\/physrev.00023.2009"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0310","first-page":"1","article-title":"Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer\u2019s disease","volume":"16","author":"Long","year":"2024","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0315","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1021\/acschemneuro.5c00484","article-title":"Antibody therapies for Alzheimer\u2019s disease: a new strategy for targeted therapy and blood-brain barrier delivery","volume":"16","author":"Feng","year":"2025","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0320","article-title":"Conditional PROTAC: recent strategies for modulating targeted protein degradation","volume":"19","author":"Yim","year":"2024","journal-title":"ChemMedChem"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0325","doi-asserted-by":"crossref","first-page":"5618","DOI":"10.3390\/molecules29235618","article-title":"Tumor-targeted cell-penetrating peptides reveal that monomethyl auristatin E temporally modulates the tumor immune microenvironment","volume":"29","author":"Mortaja","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0330","doi-asserted-by":"crossref","DOI":"10.1098\/rsfs.2016.0054","article-title":"Antibody\u2013drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment","volume":"6","author":"Howard","year":"2016","journal-title":"Interface Focus"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0335","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12070","article-title":"Extracellular vesicles as modifiers of antibody-drug conjugate efficacy","volume":"10","author":"Barok","year":"2021","journal-title":"J. Extracell Vesicles"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0340","series-title":"A Promising Strategy for Improving the Solubility and Bioavailability of Artesunate","article-title":"Exosome-drug conjugates delivery","author":"Wang","year":"2023"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0345","doi-asserted-by":"crossref","first-page":"23975","DOI":"10.1039\/D0RA02414G","article-title":"Use of exosomes as vectors to carry advanced therapies","volume":"10","author":"Sancho-Albero","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0350","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200785","article-title":"Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer\u2019s disease model","volume":"217","author":"Wang","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0355","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13024-025-00867-4","article-title":"Biomarkers and therapeutic strategies targeting microglia in neurodegenerative diseases: current status and future directions","volume":"20","author":"Noh","year":"2025","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0360","doi-asserted-by":"crossref","unstructured":"Ku\u017aniar, J., Kozubek, P., Czaja, M., Sitka, H., Kochman, U., Leszek, J., 2025. Connections between cellular senescence and alzheimer\u2019s disease\u2014a narrative review, Int. J. Mol. Sci., 26, 8638. 10.3390\/IJMS26178638.","DOI":"10.3390\/ijms26178638"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0365","doi-asserted-by":"crossref","DOI":"10.1172\/JCI158450","article-title":"Cellular senescence: a key therapeutic target in aging and diseases","volume":"132","author":"Zhang","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0370","doi-asserted-by":"crossref","unstructured":"Sahu, P., Satapathy, T., 2025. Immunopharmacology of senescence: targeting the senescence-associated secretory phenotype (SASP)\u2014a mechanism-based review, Inflammopharmacology, 33(8), 4291\u20134310. 10.1007\/S10787-025-01867-Y.","DOI":"10.1007\/s10787-025-01867-y"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0375","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.drudis.2021.06.012","article-title":"Duocarmycin-based antibody\u2013drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: pharmaceutical strategy and clinical progress","volume":"26","author":"Yao","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0380","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.3390\/cancers16152681","article-title":"Single-domain antibodies as antibody\u2013drug conjugates: from promise to practice\u2014a systematic review","volume":"16","author":"Medina P\u00e9rez","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0385","doi-asserted-by":"crossref","unstructured":"Agarwal, A., Gupta, V., Brahmbhatt, P., Desai, A., Vibhute, P., Joseph-Mathurin, N., Bathla, G., 2023. Amyloid-related imaging abnormalities in alzheimer disease treated with anti\u2013amyloid-\u03b2 therapy, 43, 10.1148\/Rg.230009.","DOI":"10.1148\/rg.230009"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00570","article-title":"Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer\u2019s disease: strategies and research directions","volume":"22","author":"Cummings","year":"2025","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0395","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.862369","article-title":"Amyloid-related imaging abnormalities with anti-amyloid antibodies for the treatment of dementia due to Alzheimer\u2019s disease","volume":"13","author":"Withington","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0400","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1227\/NEU.0b013e3182417bc2","article-title":"Effect of mannitol on cerebral blood volume in patients with head injury","volume":"70","author":"Diringer","year":"2012","journal-title":"Neurosurgery"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-018-0299-8","article-title":"Advances in developing novel therapeutic strategies for Alzheimer\u2019s disease","volume":"13","author":"Cao","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0410","doi-asserted-by":"crossref","DOI":"10.1186\/s40001-023-01512-w","article-title":"The FDA-approved anti-amyloid-\u03b2 monoclonal antibodies for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis of randomized controlled trials","volume":"28","author":"Wu","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110539","article-title":"Postulating the possible cellular signalling mechanisms of antibody drug conjugates in Alzheimer\u2019s disease","volume":"102","author":"Punyakoti","year":"2023","journal-title":"Cell. Signal."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0420","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1002\/alz.13875","article-title":"A small-molecule microtubule-stabilizing agent safely reduces A\u03b2 plaque and tau pathology in transgenic mouse models of Alzheimer\u2019s disease","volume":"20","author":"Yao","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0425","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.carrev.2023.06.010","article-title":"Delirium in older adults after percutaneous coronary intervention: prevalence, risks, and clinical phenotypes","volume":"57","author":"Park","year":"2023","journal-title":"Cardiovasc. Revasc. Med."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100150","article-title":"Donanemab: appropriate use recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"J. Prev Alzheimers Dis."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0435","doi-asserted-by":"crossref","DOI":"10.1002\/alz.054669","article-title":"A phase 1 study of AL002 in healthy volunteers","volume":"17","author":"Ward","year":"2021","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0440","doi-asserted-by":"crossref","unstructured":"Mayorga, A.J., Burgess, B., Nguyen, T., Gao, J., Salvadore, G., Romano, G., Alector, S., San Francisco, U.J., Mayorga, S.S., 2024. Baseline characteristics for INVOKE-2: a phase 2 randomized, double-blind, placebo-controlled study evaluating AL002 in early Alzheimer\u2019s disease, Alzheimer\u2019s & Dementia, 20, e095594. 10.1002\/ALZ.095594.","DOI":"10.1002\/alz.095646"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0445","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.3390\/molecules28104014","article-title":"PROTACs: emerging targeted protein degradation approaches for advanced druggable strategies","volume":"28","author":"Sincere","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0450","article-title":"Systemic administration of neurotransmitter-derived lipidoids-PROTACs-DNA nanocomplex promotes tau clearance and cognitive recovery for Alzheimer\u2019s disease therapy","volume":"13","author":"Gong","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0455","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.chembiol.2016.02.016","article-title":"Specific knockdown of endogenous tau protein by peptide-directed ubiquitin-proteasome degradation","volume":"23","author":"Chu","year":"2016","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0460","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1351792","article-title":"Selective degradation of hyperphosphorylated tau by proteolysis-targeting chimeras ameliorates cognitive function in Alzheimer\u2019s disease model mice","volume":"15","author":"Yao","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0465","doi-asserted-by":"crossref","unstructured":"Zheng, J., Tian, N., Liu, F., Zhang, Y., Su, J., Gao, Y., Deng, M., Wei, L., Ye, J., Li, H., Wang, J.Z., 2021. A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies, Signal Transd. Targ. Ther, 6, 269, 10.1038\/s41392-021-00669-2.","DOI":"10.1038\/s41392-021-00669-2"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0470","doi-asserted-by":"crossref","first-page":"586","DOI":"10.2174\/157015911798376235","article-title":"The complex and multifactorial nature of Alzheimer\u2019s disease","volume":"9","author":"Alkadhi","year":"2011","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0475","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/WCO.0000000000000912","article-title":"What is \u201cAlzheimer\u2019s disease\u201d? The neuropathological heterogeneity of clinically defined Alzheimer\u2019s dementia","volume":"34","author":"Mehta","year":"2021","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0480","doi-asserted-by":"crossref","unstructured":"Gbayisomore, T.J., Iteire, K.A., Okon, I.I., Efe, I.L., Falua, O.O., Opeyemi, W.O., Gideon, A.S., Ajayi, R.O., Inusah, A.-H.S., 2024. Innovative approaches and challenges in antibody-based therapeutics for Alzheimer\u2019s disease, INNOSC Ther. Pharmacol. Sci., 7(3), 2953. 10.36922\/ITPS.2953.","DOI":"10.36922\/itps.2953"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0485","article-title":"Combination drug therapy for the management of alzheimer\u2019s disease","volume":"21","author":"Tanvir Kabir","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody\u2013Drug conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0495","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11481-006-9025-3","article-title":"Blood-brain barrier: structural components and function under physiologic and pathologic conditions","volume":"1","author":"Persidsky","year":"2006","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0500","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s12551-021-00903-9","article-title":"Structural biology of cell surface receptors implicated in Alzheimer\u2019s disease","volume":"14","author":"Hermans","year":"2021","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0505","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2023.1206572","article-title":"Current and future therapeutic strategies for Alzheimer\u2019s disease: an overview of drug development bottlenecks","volume":"15","author":"Peng","year":"2023","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0510","article-title":"AI-powered integration of multi-source data for TAA discovery to accelerate ADC and TCE drug development (I)","author":"Xie","year":"2025","journal-title":"TAA Target Identification and Prioritization"},{"key":"10.1016\/j.neuroscience.2025.12.053_b0515","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.tips.2025.10.005","article-title":"Artificial intelligence in antibody\u2013drug conjugate development","volume":"46","author":"Wang","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0520","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuroscience.2025.12.053_b0525","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s13311-022-01185-z","article-title":"Heterogeneity in Alzheimer\u2019s disease diagnosis and progression rates: implications for therapeutic trials","volume":"19","author":"Duara","year":"2022","journal-title":"Neurotherapeutics"}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452225012205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452225012205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T09:40:39Z","timestamp":1775900439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452225012205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":105,"alternative-id":["S0306452225012205"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2025.12.053","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody drug conjugates in Alzheimer\u2019s disease: emerging strategies and future directions","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2025.12.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Brain Research Organization (IBRO). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}